A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis

Eligibility Criteria

• * Body mass index within the range of \>= 25 and \<=45 kilograms per square meter (kg/m\^2)
• * MASH with fibrosis score of F3 or F4 confirmed by transient elastography measurement \>=12.0 kPa and \<=25.0 kPa
• * Agreement to adhere to the contraception requirements
• * Weight gain or loss \>5% in the 3 months prior to baseline or \>10% in the 6 months prior to baseline
• * Bariatric surgery within 1 year prior to baseline
• * Current signs or prior history of decompensated liver disease
• * Complications or clinical evidence of portal hypertension
• * Lack of peripheral venous access
• * Other causes of liver disease based on medical history and/or centralized review of liver histology
• * History of liver transplantation
• * Current or prior history of hepatocellular carcinoma (HCC)
• * Uncontrolled hypertension
• * Concomitant Type 1 diabetes, or Type 2 diabetes with HbA1c \>10%
• * History of malignancy within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
• * Current, significant alcohol consumption or a history of significant alcohol consumption for a period of more than 3 consecutive months any time within 1 year prior to screening
• * Initiation of a medication of an antidiabetic, weight loss, lipid-modifying or anti-depressant drug class
• * Active tuberculosis requiring treatment within the 12 months prior to baseline
• * History of organ transplant